中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
17期
22-23
,共2页
罗氟司特%糖皮质激素%支气管哮喘%炎性细胞因子%肺功能
囉氟司特%糖皮質激素%支氣管哮喘%炎性細胞因子%肺功能
라불사특%당피질격소%지기관효천%염성세포인자%폐공능
roflumilast%glucocorticoids%bronchial asthma%inflammatory cytokines%lung function
目的：评价新型磷酸二酯酶-4（PDE-4）抑制剂罗氟司特治疗糖皮质激素抵抗型支气管哮喘的临床疗效。方法选择2012年1月至2013年12月糖皮质激素抵抗型支气管哮喘患者84例，按照随机数字表法分为对照组和治疗组，各42例。对照组给予氨茶碱400 mg/d口服和沙美特罗100μg/d吸入，急性发作时予沙丁胺醇200~800μg/d吸入；治疗组在上述治疗基础上联合使用罗氟司特片500μg/d。两组疗程均为30 d。评价临床疗效，记录治疗前后哮喘临床评分、血清炎性细胞因子的水平及肺功能指标的变化，以及不良反应的发生情况。结果治疗30 d后，治疗组总有效率为85.71%，显著高于对照组的35.71%（ P<0.05）；两组患者临床哮喘评分、炎性细胞因子水平、肺功能指数均较治疗前有改善（ P<0.05），且治疗组改善更显著（ P<0.05）；两组不良反应发生率无明显差异（ P＞0.05）。结论罗氟司特治疗糖皮质激素抵抗型支气管哮喘的临床疗效好，且不良反应少，值得临床推广。
目的：評價新型燐痠二酯酶-4（PDE-4）抑製劑囉氟司特治療糖皮質激素牴抗型支氣管哮喘的臨床療效。方法選擇2012年1月至2013年12月糖皮質激素牴抗型支氣管哮喘患者84例，按照隨機數字錶法分為對照組和治療組，各42例。對照組給予氨茶堿400 mg/d口服和沙美特囉100μg/d吸入，急性髮作時予沙丁胺醇200~800μg/d吸入；治療組在上述治療基礎上聯閤使用囉氟司特片500μg/d。兩組療程均為30 d。評價臨床療效，記錄治療前後哮喘臨床評分、血清炎性細胞因子的水平及肺功能指標的變化，以及不良反應的髮生情況。結果治療30 d後，治療組總有效率為85.71%，顯著高于對照組的35.71%（ P<0.05）；兩組患者臨床哮喘評分、炎性細胞因子水平、肺功能指數均較治療前有改善（ P<0.05），且治療組改善更顯著（ P<0.05）；兩組不良反應髮生率無明顯差異（ P＞0.05）。結論囉氟司特治療糖皮質激素牴抗型支氣管哮喘的臨床療效好，且不良反應少，值得臨床推廣。
목적：평개신형린산이지매-4（PDE-4）억제제라불사특치료당피질격소저항형지기관효천적림상료효。방법선택2012년1월지2013년12월당피질격소저항형지기관효천환자84례，안조수궤수자표법분위대조조화치료조，각42례。대조조급여안다감400 mg/d구복화사미특라100μg/d흡입，급성발작시여사정알순200~800μg/d흡입；치료조재상술치료기출상연합사용라불사특편500μg/d。량조료정균위30 d。평개림상료효，기록치료전후효천림상평분、혈청염성세포인자적수평급폐공능지표적변화，이급불량반응적발생정황。결과치료30 d후，치료조총유효솔위85.71%，현저고우대조조적35.71%（ P<0.05）；량조환자림상효천평분、염성세포인자수평、폐공능지수균교치료전유개선（ P<0.05），차치료조개선경현저（ P<0.05）；량조불량반응발생솔무명현차이（ P＞0.05）。결론라불사특치료당피질격소저항형지기관효천적림상료효호，차불량반응소，치득림상추엄。
Objective To evaluate the clinical efficacy of roflumilast as a new phosphodiesterase -4 inhibitor in treating glucocorti-coid-resistant bronchial asthma. Methods 84 patients with glucocorticoid-resistant bronchial asthma from January 2012 to December 2013 were selected and randomly divided into the control group and the treatment group according to the random number table, 42 cas-es in each group. The control group was treated with oral aminophylline 400 mg/d and inhalation of salmeterol 100 μg/d, in acute at-tack, inhaling salbutamol 200-800μg/d. The treatment group was combined with roflumilast 500μg/d on the basis of above mentioned treatment. The course of treatment in the two groups was 30 d. The clinical effects were evaluated. The asthma clinical scores, serum levels of inflammatory cytokines and change of pulmonary function before and after treatment were recorded. The occurrence situation of adverse reactions was recorded. Results The total effective rate after 30 d treatment in the treatment group was 85. 71%, which was significantly higher than 35. 71% in the control group ( P<0. 05 ) . The clinical asthma score, serum levels of inflammatory cytokines and lung function indices after treatment in the two groups were improved compared with before treatment ( P<0. 05 ) , moreover the improve-ment in the treatment group was more significant, the differences between the two groups had statistical significance ( P<0. 05 ) . The oc-currence rate of adverse reactions had no statistically significant difference ( P>0. 05 ) . Conclusion Roflumilast has better clinical effi-cacy in treating glucocorticoid-resistant bronchial asthma and less adverse reactions, and deserves to be clinically promoted.
